Pathstone Holdings’s Myriad Genetics MYGN Stock Holding History

Pathstone Holdings’s Portfolio MYGN Stock Details MYGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-30,996	Closed	-$191K	–	2301
2025 Q4	$191K	Sell	30,996 -31,412	-50%	-$228K	﹤0.01%	2116
2025 Q3	$451K	Buy	+62,408	New	+$371K	﹤0.01%	1818

Other funds holding MYGN

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

GCM

Glenview Capital Management New York $3.98B AUM 20.52% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Pathstone Holdings's MYGN Position: Q1 2026 in Review

Pathstone Holdings sold out of Myriad Genetics (MYGN) in Q1 2026, closing a stake of 30,996 shares — an estimated $191K sold.

Pathstone Holdings first reported a position in MYGN in Q3 2025 and held it in 2 quarters. The position peaked at $451K in Q3 2025. 202 funds tracked by Wall St. Rank hold MYGN as of Q1 2026.

Pathstone Holdings reported no remaining Myriad Genetics position as of Q1 2026 after selling out during the quarter.
Pathstone Holdings sold 30,996 Myriad Genetics shares in Q1 2026, an estimated $191K.
Pathstone Holdings first reported a position in Myriad Genetics in Q3 2025 and held it in 2 quarters.
Pathstone Holdings's Myriad Genetics position peaked at $451K in Q3 2025.
202 funds tracked by Wall St. Rank held Myriad Genetics as of Q1 2026.

Based on Pathstone Holdings's 13F filing for Q1 2026, filed 11 May 2026.